The U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulne...
FILE PHOTO: The corporate logo of the U.S. Food and Drug Administration is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo
- The U.S. Food and Drug Administration on Thursday said cybersecurity vulnerabilities were identified in Medtronic Plc’s implantable cardiac devices, clinic programmers, and home monitors. But, the FDA recommended the usage of the devices and said the medical device maker was developing updates to further mitigate those vulnerabilities. The health regulator added it was not aware of any reports of patients being harmed.
Last year, Medtronic disabled internet updates for some 34,000 CareLink programming devices that healthcare providers around the world use to access implanted pacemakers, saying the system was vulnerable to cyberattacks. Medical device makers have bolstered efforts to mitigate product security vulnerabilities in recent years following a flurry of warnings from security researchers who have identified bugs in devices like the Medtronic implant programmers.Reporting by John Benny in Bengaluru; Editing by Chris Reese
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves the first drug designed to treat postpartum depressionThe FDA approved the first drug specifically for postpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.
Read more »
Outgoing FDA chief: Altria bait-and-switched me with $12.8 billion Juul investmentFood and Drug Administration (FDA) Commissioner Scott Gottlieb said on Tuesday that tobacco giant Altria went back on its promise to clamp down on vape pods with its $12.8 billion investment in e-cigarette decacorn Juul Labs.
Read more »
Jazz Pharma's sleep disorder treatment gets FDA nodThe U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc's t...
Read more »
FDA issues warning to two breast implant makers over safety concernsLess than a week before a major hearing on breast implant safety, the FDA issued two warning letters to implant manufacturers, citing their failure to do proper safety studies.
Read more »
FDA approves first treatment for postpartum depressionThe FDA has approved a new medication called Zulresso, a completely new class of drug designed specifically to treat postpartum depression. It’s a one-time infusion given in a hospital over two and a half days.
Read more »
FDA puts partial hold on clinical trials of AbbVie's cancer drugAbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partia...
Read more »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Read more »